GlaxoSmithKline v. Teva: Carvedilol Patent Dispute Ends in Confidential Settlement After 11 Years

Case Overview

After more than a decade of litigation spanning 4,240 days, GlaxoSmithKline’s pharmaceutical patent infringement battle against Teva Pharmaceutical Industries concluded not with a courtroom verdict, but with a confidential settlement executed on February 10, 2026. Filed in the District of Delaware on July 3, 2014, the dispute centered on USRE040000E — a reissued U.S. patent covering COREG® (carvedilol) tablets in multiple dosage strengths — and Teva’s alleged infringement through its generic formulations.

The case, GlaxoSmithKline LLC v. Teva Pharmaceutical Industries, Ltd. (Case No. 1:14-cv-00878), stands as a textbook example of pharmaceutical patent litigation complexity: prolonged procedural battles, significant legal resources deployed on both sides, and ultimately, a resolution shielded from public scrutiny. For patent attorneys, in-house counsel, and R&D teams navigating the generic drug landscape, this case carries instructive lessons about ANDA litigation strategy, reissued patent assertions, and the calculus of settlement versus trial in high-stakes pharmaceutical IP disputes.

The Parties

Patents at Issue

This landmark case involved U.S. Patent No. USRE040000E (reissued from application number US10/721020), a reissued patent covering carvedilol formulations including 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg tablets — the precise dosage strengths commercialized under the COREG® brand. Reissued patents carry particular litigation significance: they reflect USPTO corrections to original grants, and their claim scope frequently becomes a contested battleground regarding whether the reissue broadened or narrowed original claims.

• • USRE040000E — Reissued patent covering Carvedilol formulations.

The Verdict & Legal Analysis

Outcome

On February 10, 2026, the parties filed a Joint Stipulation and Order of Dismissal with Prejudice, resolving all claims, counterclaims, defenses, motions, and petitions between GSK and Teva. The resolution rests on a Confidential Settlement Agreement, the specific terms of which — including any financial compensation, licensing arrangements, or authorized generic provisions — were not disclosed in public court filings.

The fee-sharing arrangement — each side bearing its own costs — is neither an admission of liability nor an indicator of outcome favorability for either party. It is, however, a standard feature of negotiated pharmaceutical patent settlements.

Key Legal Issues

The case was brought as a straight infringement action — GSK asserting that Teva’s ANDA filing and intended generic carvedilol commercialization constituted infringement of the reissued patent. In Hatch-Waxman litigation, an ANDA filer’s Paragraph IV certification (asserting patent invalidity or non-infringement) automatically triggers the brand’s right to sue, initiating a 30-month stay of FDA approval.

The reissued patent designation (USRE040000E) is particularly significant from a legal standpoint. Reissued patents are subject to intervening rights doctrines — both absolute and equitable — which can limit the patent holder’s recovery against parties who relied on the original patent’s claim scope. While the confidential settlement prevents public examination of claim construction rulings or validity findings, the case reinforces that reissued patents remain viable — and contested — assertion vehicles for brand manufacturers.